About
Us
YOUR TRUSTED PARTNER IN GENERIC PHARMACEUTICALS
Solaris Pharma is committed to enhancing healthcare access through the development and supply of essential, in demand medicines. We operate with a strong emphasis on quality, regulatory compliance, and operational excellence, ensuring that our generic portfolio is delivering global standards for safety, efficacy, and reliability.
Our business model emphasizes strategic sourcing, lifecycle management, and continuous improvement across manufacturing and distribution. By combining technical expertise with disciplined execution, Solaris Pharma delivers value across the pharmaceutical supply chain.
Our Mission
Solaris Pharma Corporation is committed to developing and delivering a broad portfolio of complex generic and specialty pharmaceutical products that provide patients with high-quality, affordable, and effective therapeutic alternatives—supported by scientific excellence, regulatory rigor, and manufacturing reliability.
Solaris Pharma Corporation is currently developing several topical, sterile and tablet products, which are in different stages of development. The company has a dedicated team of committed and well-trained scientists along with experienced program managers and regulatory personnel who provide a robust product development process. The entire end-to-end product development process has been validated through multiple product approvals. A scalable commercial infrastructure is in place to market our approved products. The commercial team has reinforced our success of timely product approvals by successfully launching multiple products under the Solaris label into the market. Solaris has established an excellent reputation of being a dependable supplier, trusted for consistent quality and reliable performance.
THE DOSAGE FORMS THAT ARE BEING DEVELOPED AT OUR FACILITY INCLUDE:
About Our COmpany
Our History
May 13, 2026
Tazarotene Cream, 0.05%
April 13, 2026
Brivaracetam Tablets 100mg
April 13, 2026
Brivaracetam Tablets 75mg
April 13, 2026
Brivaracetam Tablets 50mg
April 13, 2026
Brivaracetam Tablets 25mg
April 13, 2026
Brivaracetam Tablets 10mg
April 6, 2026
Clarithromycin Extended-Release Tablets 500mg
April 6, 2026
Clarithromycin Tablets 500mg
April 6, 2026
Clarithromycin Tablets 250mg
January 26, 2026
Nitroglycerin Ointment 0.4%
December 29, 2025
Moxifloxacin Tablets 400mg
June 10, 2025
Dicyclomine HCl Capsules 20mg
June 10, 2025
Dicyclomine HCl Capsules 10mg
March 18, 2024
Estradiol Gel 0.06%
November 3, 2023
Neomycin Sulfate Tablets 500mg
February 16, 2024
Tazarotene Gel 0.10%
February 1, 2024
Tazarotene Gel 0.05%
April 1, 2022
Clindamycin Phosphate & Tretinoin Gel 1.2%/0.025%
September 17, 2021
Metronidazole Vaginal Gel 0.75%
July 7, 2021
Clindamycin Phosphate Gel 1%, 75ml
EXPERIENCED LEADERSHIP
Solaris Pharma is led by an experienced management team with deep expertise in generic pharmaceuticals, regulatory affairs, quality assurance, supply chain management, and commercial operations.
SHALIN JANI, M.S.
PRESIDENT & CEO
KAMLESH AMIN, PH.D.
VICE PRESIDENT, AR&D
JOE LIN
DIRECTOR OF FINANCE
ROMIT JANI M.S.
SR DIRECTOR OF FORMULATION DEVELOPMENT
RUTH MARRERO, PHR
SR HUMAN RESOURCE MANAGER
VEERA PALACHARLA
SR MANAGER OF REGULATORY AFFAIRS
ROB MATTISON
SR Director of Sales and Commercial Operations
KAMAL MEHTA
Associate Director of Quality Assurance
Leadership
PARTNERS & INVESTORS